We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunochromatographic Lateral Flow Device Developed for Cholera

By LabMedica International staff writers
Posted on 28 Apr 2014
Print article
Image: Vibrio cholerae bacterial colonies cultivated on Thiosulfate-Citrate-Bile-Sucrose (TCBS) agar medium (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
Image: Vibrio cholerae bacterial colonies cultivated on Thiosulfate-Citrate-Bile-Sucrose (TCBS) agar medium (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
Currently, the gold standard to detect Vibrio cholerae is still the bacterial culture method, which is laborious, time-consuming and lacks sensitivity; however several modern diagnostic methods have been developed.

Cholera is an acute malignant infectious disease caused by the bacteria V. cholerae leading to severe dehydrating diarrhea and vomiting, even high rates of mortality in some cases. The prevention of the epidemic disease is achievable if proper sanitation practices are followed provided the accurate and prompt diagnosis of each prevalent serotype in cholera epidemics.

Scientists at the Chongqing Medical University (China) collaborating with colleagues at Artron BioResearch Inc. (Burnaby, BC, Canada) developed an immunochromatographic test format for the V. cholerae O1 serotype Ogawa diagnosis and which may provide the need for better epidemic prevention and early response.

Monoclonal antibodies were raised in conventional method and subsequently screened for a matched pair. A variety of related and unrelated bacteria strains were employed to test their sensitivity, specificity by indirect enzyme-linked immunosorbent assay (ELISA). A total of 726 diarrhea patients’ feces samples from July 2012 to September 2012 were examined by an in-house Immunochromatographic Lateral Flow Device, commercial strips from Zhuangdi Haohe Biological Medicine Co., Ltd. (Beijing, China) and standard bacterial culture method in parallel for comparison. The human fecal samples were used to test the final lateral-flow device product to satisfy the measurement requirement.

To perform a test, after full contact with the sample solution, the strips were kept at room temperature for five minutes. Two bands that appeared at both the test and control sites represented a positive test result. Only one band at the control location represents a negative test result. The absence of a line at the control site means the test was invalid. The detection threshold for bacterial culture of the strip was 1.0 × 104 colony forming units (cfu)/mL, which is higher than the current stipulated threshold of 1.0 × 105 cfu/mL.

The authors concluded that they had successfully developed rapid diagnostic test (RDT) strips for cholera by conducting systematic evaluation to assess its specificity, sensitivity and reliability. The product was capable of distinguishing the V. cholerae O1 Ogawa and V. cholerae O1 Inaba, which filled the gaps of the area in rapid cholera diagnosis. Overall, the outcome confirmed that the RDT has superior detection aspects than other parallel commercial products. The study was published in the April 2014 issue of the journal Clinical Biochemistry.

Related Links:
Chongqing Medical University
Artron BioResearch Inc.
Zhuangdi Haohe Biological Medicine Co., Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.